Coherus Biosciences | CHRS - Assets


Coherus Biosciences reported $258.34M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Fujifilm JPY 6.05T 170.69B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026
Zoetis USD 15.15B 313M Mar/2026